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Abstract
Background: Variant translocations t(9;22) occur in 5 to 10% of newly diagnosed CMLs and
additional genetic changes are present in 60–80% of patients in blast crisis (BC). Here, we report
on a CML patient in blast crisis presenting with a four-way variant t(9;22) rearrangement involving
the EVI1 locus.
Methods: Dual-colour Fluorescence In Situ Hybridisation was performed to unravel the different
cytogenetic aberrations. Expression levels of EVI1 and BCR/ABL1 were investigated using real-time
quantitative RT-PCR.
Results: In this paper we identified a patient with a complex 4-way t(3;9;17;22) which, in addition
to BCR/ABL1 gene fusion, also resulted in EVI1 rearrangement and overexpression.
Conclusion: This report illustrates how a variant t(9;22) translocation can specifically target a
second oncogene most likely contributing to the more aggressive phenotype of the disease.
Molecular analysis of such variants is thus warranted to understand the phenotypic consequences
and to open the way for combined molecular therapies in order to tackle the secondary oncogenic
effect which is unresponsive to imatinib treatment.
Background
Chronic myeloid leukemia (CML) has a typical indolent
chronic phase that may last several years but will ulti-
mately progress into acute myeloid leukemia (AML) or
acute lymphoid leukemia (ALL). The typical associated
translocation t(9;22)(q34;q11), leading to the BCR/ABL1
fusion gene and constitutive activation of the ABL1 tyro-
sine kinase on 9q34, is considered to be the initial trans-
forming event [1]. Instead of the classical t(9;22)
translocation, cryptic and variant translocations occur in
about 5 to 10 % of all CML cases. CML in blast crisis is
often accompanied by the presence of additional chromo-
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some aberrations [2]. Amongst those, activation of the
EVI1  gene has been reported in a small percentage of
patients [3]. Ectopic expression of the EVI1 gene is usually
due to recurrent 3q26 translocations such as the
t(3;21)(q26;q22) (AML1/EVI1) and the
inv(3;3)(q21q26). Transcriptional activation of EVI1 can
also occur in the absence of genomic rearrangement at
this locus [4]. In general, EVI1 upregulation confers a poor
prognosis in hematological malignancies [5].
In this study, we describe how the molecular characteriza-
tion of the translocation breakpoints of a variant t(9;22)
in a patient with CML in blast crisis lead to the discovery
of involvement of the EVI1  locus. We also discuss the
importance of the study of secondary genomic events
present or occurring during blast crisis with respect to the
development of strategies for treatment of CML patients
in blast crisis.
Methods
Patient material
A diagnostic bone marrow sample was obtained from a
patient who presented with features of chronic myeloid
leukemia in blast crisis. The patient died nine months
after diagnosis.
This study was approved by the Ethical Committee of the
Ghent University Hospital (2003/273).
Cytogenetic analysis
Cytogenetic analysis of the diagnostic bone marrow sam-
ple was performed according to standard methods. A 24-
hour bone marrow culture was performed and chromo-
somes were G-banded with a trypsin-Giemsa stain (GTG-
banding). Fifteen metaphases were analyzed and the kary-
otype was described according to the International System
for Human Cytogenetic Nomenclature [6].
Fluorescence in situ hybridisation analyses
Dual-colour Fluorescence In Situ Hybridisation (FISH)
was performed on the diagnostic bone marrow sample
using a t(9;22) specific BCR/ABL1 dual color, dual fusion
probe (Abbott Vysis, Germany). Commercial Whole
Chromosome Paints (WCP) for chromosomes 3, 9, 17
and 22 (Metasystems, Germany) were used to unravel the
translocations in the bone marrow sample. A commercial
centromeric probe for chromosome 3 (Abbott Vysis, Ger-
many) was used to facilitate identification of chromo-
some 3.
Detection of EVI1 rearrangement was done using the fol-
lowing BAC clones: RP11-694D5 (position 169.8 Mb,
centromeric of EVI1), RP11-82C9 (position 170.3 Mb,
EVI1 overlapping) and RP11-362K14 (position 171.1 Mb,
telomeric of EVI1) (NCBI genome browser Build 36.1).
All non-commercial clones were acquired from the Sanger
Wellcome Trust Institute, Hinxton, Cambridge (United
Kingdom). The EVI1 specific probes were labelled with
biotin-16-dUTP (Roche Diagnostics, Belgium) and digox-
igenin-12-dUTP (Roche Diagnostics, Belgium) and FISH
analysis was performed as previously described [7,8].
Biotin labelled probes were detected with Fluorescein Iso-
ThioCyanate (FITC)-conjugated anti-biotin antibodies
(Invitrogen, Belgium) and digoxigenin labelled probes
with TetramethylRhodamine IsoThioCyanate (TRITC)-
conjugated anti-digoxigenin antibodies (Roche Diagnos-
tics, Belgium). A minimum of 100 nuclei and a minimum
of 5 metaphases were scored using a fluorescence micro-
scope (Axioplan 2, Zeiss, Belgium) and images were cap-
tured using a black and white CCD camera and images
were processed with the ISIS software program (MetaSys-
tems, Germany).
Real-time quantitative RT-PCR
Total RNA was extracted from the diagnostic bone mar-
row sample using the Trizol LS reagent (Invitrogen, Bel-
gium) according to the manufacturer's recommendations.
cDNA was prepared from 2 μg of total RNA with the
iScript cDNA Synthesis Kit (Bio-Rad, Belgium) according
to the manufacturer's instructions.
Real-time quantitative RT-PCR (qRT-PCR) for the EVI1
(forward: 5'-GTACTTGAGCCAGCTTCCAACA-3', reverse:
5'-CTTCTTGACTAAAGCCCTTGGA-3', exon 1b-2), cEVI1
(forward: 5'-ACCCACTCCTTTCTTTATGGACC-3', reverse:
5'-TGATCAGGCAGTTGGAATTGTG-3', exon 8–9), MDS1/
EVI1  (forward: 5'-GAAAGACCCCAGTTATGGATGG-3',
reverse: 5'-GTACTTGAGCCAGCTTCCAACA-3', exon 2
MDS1 – exon 2 EVI1) and MDS1 (forward: 5'-GAAAGAC-
CCCAGTTATGGATGG-3', reverse: 5'-TCTCTTC-
CCCAAATACAACCAAG-3', exon 2–3) transcripts was
performed as previously described [9,10]. Cell line K562
was used as a positive control and reference, its EVI1
expression level was set to 1.
QRT-PCR for the BCR/ABL1 fusion transcript was done
according to the Europe Against Cancer program (EAC)
protocol [11].
Results
Detailed cytogenetic analysis of 15 G-banded metaphases
from the diagnostic bone marrow revealed the following
karyotype: 50, XY, add(3)(q26),+8,
add(9)(q34),+add(9)(q34),+10,+12, del(16)(q23),-17,
der(22)t(9;22)(q34;q11),+mar [cp15] (Fig. 1).
FISH with the BCR/ABL1  dual-color dual-fusion probe
revealed two fusion signals together with a single green
and red signal in interphase nuclei. In metaphases, one
fusion was located on the Philadelphia chromosomeBMC Cancer 2008, 8:193 http://www.biomedcentral.com/1471-2407/8/193
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whereas the second fusion signal was present on the
marker chromosome instead of on the
der(9)t(9;22)(q34;q11.2) (Fig. 2A). Real-time quantita-
tive RT-PCR (qRT-PCR) confirmed the presence of the
BCR/ABL1 fusion and revealed a major MBCR transcript
(data not shown).
Further FISH characterisation of this t(9;22) variant trans-
location, revealed involvement of chromosomes 3 and
17. FISH analysis with two probe combinations for the
EVI1 locus (EVI1 centromeric and overlapping; EVI1 telo-
meric and overlapping) revealed a breakpoint 5' and telo-
meric of EVI1  and translocation of the telomeric
chromosome 3 segment to the der(9) (Fig. 2B). The trans-
location of the ABL1/BCR segment from the der(9) to the
der(17) was accompanied by translocation of the distal
17q segment immediately distal to the EVI1 locus on the
der(3). FISH with whole chromosome paints confirmed
these observations (Fig. 2C–D).
Based on these FISH analyses, the karyotype was revised as
50, XY, der(3)(3pter→q26::17q22→qter),+8,
der(9)(9pter→q34::3q26→qter),+der(9)(9pter→q34::3q
26→qter),+10,+12, del(16)(q23),
der(17)(17pter→q22::9q34q34::22q11→qter),
der(22)(22pter→q11::9q34→qter) [cp15].
Ectopic expression of the full length EVI1 transcript was
detected with qRT-PCR using the 5' located EVI1 primer
pair (Fig. 3A). qRT-PCR with the 3' located cEVI1 primer
pair was able to detect additional ectopic expression 5'
EVI1 variant transcripts (Fig. 3B). No expression of the
MDS1/EVI1 or MDS1 transcripts could be detected with
qRT-PCR (data not shown).
Discussion
We describe the molecular characterization of a complex
4-way t(3;9;17;22) translocation, which in addition to
BCR-ABL1 gene fusion also resulted in EVI1 overexpres-
Representative karyotype from bone marrow of the patient Figure 1
Representative karyotype from bone marrow of the patient. Arrows indicate a derivative chromosome 3 with an 
addition, a marker chromosome, two derivative chromosomes 9 (der(9)), del(16)(q23), the loss of a chromosome 17 and a Ph-
chromosome.BMC Cancer 2008, 8:193 http://www.biomedcentral.com/1471-2407/8/193
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FISH analysis on metaphases from bone marrow slides Figure 2
FISH analysis on metaphases from bone marrow slides. (A) FISH with the dual color, dual fusion BCR/ABL1 probe gen-
erates two fusion signals (ABL1 red and BCR green): one on a marker chromosome [der(17)] and one on the Ph-chromosome, 
one red signal on a normal chromosome 9 and one green signal on a normal chromosome 22. (B) EVI1 specific probes RP11-
362K14 (red, distal from EVI1) and RP11-82C9 (green, EVI1 overlapping) showed a co-localized red-green signal on the normal 
chromosome 3, a green signal on the derivative chromosome 3 [der(3)] and two red signals translocated onto identical but 
unidentified chromosomes [der(9)]. (C) FISH with WCPs for chromosomes 3 (purple), 9 (red) and 22 (green), revealed one 
normal chromosome 9, two derivative chromosomes 9 [der(9)], a der(17) containing a piece of chromosome 22 and chromo-
some 9, a normal chromosome 3 (norm 3), a derivative chromosome 3 [der(3)] and a Ph-chromosome. (D) WCP of chromo-
somes 17 (green) and 22 (red), combined with a purple centromeric probe for chromosome 3, indicated that a translocation 
between the long arm of chromosome 3 and the long arm of chromosome 17 had occurred as well as a translocation between 
chromosome 17 and 22.BMC Cancer 2008, 8:193 http://www.biomedcentral.com/1471-2407/8/193
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sion. Based on FISH and karyotype data we propose a two-
step mechanism [12] for generating the complex 4-way
translocation, i.e. first the formation of a classical t(9;22),
followed by a subsequent three-way translocation involv-
ing chromosomes 3, 17 and the derivative chromosome 9.
The latter rearrangement was the result of translocation of
the ABL1/BCR segment from the der(9) to chromosome
17, translocation of the distal 17q segment to the 3q26
locus on chromosome 3 and translocation of the distal
part of chromosome 3 to the der(9). Further molecular
investigation using FISH indicated that the 3q26 break-
point located immediately distal of the 5' end of the EVI1
locus. As expected qRT-PCR revealed ectopic expression of
EVI1. A third and final step encompassed the duplication
of the der(9) in this patient (Fig. 4A–C).
EVI1  overexpression is a well established unfavourable
prognostic marker in AML patients, and is often found in
progressive or blast crisis CML [4,13,14]. It is therefore
likely that, like for the additional alterations such as tri-
somy 8 and isochromosome 17q, the observed EVI1 over-
expression contributes to the aggressive phenotype of the
blastic CML phase. The presence of the additional cytoge-
netic abnormality del(16)(q23) in this patient could also
negatively influence disease progression.
Apart from the known recurrent secondary changes occur-
ring during progression or blast phase in CML, most addi-
tional rearrangement breakpoints have remained
unexplored at the molecular level. It can be assumed that
such breakpoints target specific genes leading to addi-
tional proliferative or survival advantage to the tumour
cell. The present study illustrates the importance of char-
acterization of such secondary rearrangements or break-
points in order to understand the molecular basis of the
acute phase in CML.
Given the progress in CML treatment due to the develop-
ment of 1st and 2nd generation small molecules (TK-inhib-
itors) such as imatinib, nilotinib and dasatinib [15],
targeting of such additional oncogenic events now repre-
sents a new challenge for future CML treatment. Even
though currently the number of targeted therapies is still
limited, it can be anticipated that in the future, combina-
tion therapies with imatinib and compounds targeted at
the secondary changes can become a reality. Therefore, we
propose a systematic testing of 3q26 aberrations in CML
patients in blast crisis or CML patients with an evolution-
ary disease course. Since to date only a few target genes of
the transcriptional repressor EVI1 are known [16], further
research will be needed to identify more genes implicated
in EVI1 pathogenesis thus opening the way for develop-
ment of novel targeted therapeutics.
Conclusion
In conclusion, we report on a CML patient in blast crisis
presenting with a three-step variant Ph-positive chromo-
some rearrangement, involving the EVI1 locus. This report
shows that the variant translocation can specifically target
a second oncogene which most likely contributes to the
EVI1 expression measured by qRT-PCR Figure 3
EVI1 expression measured by qRT-PCR. (A) qRT-PCR 
for EVI1 with primers located 5' of the transcript revealed 
ectopic EVI1 expression in the patient after normalization 
with several household genes, the cell line K562 was used as 
a positive control, the K562 expression was set to 1, Y-axis 
in log-scale (B) EVI1 qRT-PCR with primers located 3' of the 
transcript (cEVI1) indicated an ectopic expression of a 5' var-
iant EVI1 transcript, the cell line K562 was used as a positive 
control, the K562 EVI1 expression was set to 1, Y-axis in log-
scale.BMC Cancer 2008, 8:193 http://www.biomedcentral.com/1471-2407/8/193
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Schematic representation of possible generation of the 4-way t(3;9;17;22) Figure 4
Schematic representation of possible generation of the 4-way t(3;9;17;22). (A) Formation of the t(9;22)(q34, q11). 
(B) Three-way translocation involving the EVI1 locus on 3q26, part of the distal long arm of chromosome 17 and the 
der(9)t(9;22). (C) Representation of the derivative chromosomes 3, 9, 17 and 22 in our patient.BMC Cancer 2008, 8:193 http://www.biomedcentral.com/1471-2407/8/193
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more aggressive phenotype of the leukemia. Molecular
analysis of t(9;22) variants is needed to understand its
phenotypic consequences and to open the way to com-
bined molecular therapies in order to counteract the sec-
ondary oncogenic effect which is unresponsive to
imatinib treatment.
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